Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 27;23(3):533.
doi: 10.3390/molecules23030533.

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G de la Torre  1 , Fernando Albericio  2   3
Affiliations
Review

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G de la Torre et al. Molecules. .

Abstract

This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules.

Keywords: API; biologics; chemical entities; drug discovery; peptide; small molecules.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
New Chemical Entities and Biologics approved by the FDA in the last two decades [1,2].
Figure 2
Figure 2
Structure of peptides. In red the non-proteinogenic or modified amino acids.
Figure 3
Figure 3
Structure of amino acid-based drugs. In red the amino acid.
Figure 4
Figure 4
Structure of deutetrabenazine.
Figure 5
Figure 5
Structure of drugs inspired by natural products.
Figure 6
Figure 6
Structure of drugs that contain the 2-amine-pyrimidine (in red) moiety.
Figure 7
Figure 7
Structure of enasidenib that contains the triazine (in red) scaffold.
Figure 8
Figure 8
Structure of drug combination for treatment of hepatitis C.
Figure 9
Figure 9
Structure of the drug combination for infections.
Figure 10
Figure 10
Structure of oxacin (in red) based drugs.
Figure 11
Figure 11
Structure of drugs derived of nitroimidazole (in red).
Figure 12
Figure 12
Structure of drugs derived of the N-phenyl-pyrazole (in red) structure.
Figure 13
Figure 13
Structure of midostaurin, neratinib, acalabrutinib, and latanoprostene.
See this image and copyright information in PMC

References

    1. U.S. Food and Drug Administration (FDA) [(accessed on 27 February 2018)]; Available online: http://www.accessdata.fda.gov/scripts/cder/daf/
    1. Mullard A. 2017 FDA drug approvals. Nat. Rev. Drug Discov. 2018;17:81–85. doi: 10.1038/nrd.2018.4. - DOI - PubMed
    1. Jarvis L.M. The year in new drugs. Chem. Eng. News. 2018;January 22:26–30.
    1. U.S. Food and Drug Administration (FDA) [(accessed on 27 February 2018)]; Available online: Https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTo....
    1. Beck A., Goetsch L., Dumontet C., Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 2017;16:315–337. doi: 10.1038/nrd.2016.268. - DOI - PubMed

MeSH terms

Substances